Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.61 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.61 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.61 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.61 |
| ▸ | STRADA | Q7RTN6 | 1/20 | 0.61 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9111868 | 0.90 | MAPKAPK2 (0.62) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL9110526 | 0.90 | MAPKAPK2 (0.64) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL9109111 | 0.90 | MAPKAPK2 (0.66) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL24461663 | 0.88 | MAPKAPK5 (0.59) | MAPK14MAPKAPK2 | |
| SCHEMBL4377493 | 0.86 | MAPK14 (0.82) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL24461461 | 0.85 | MAPKAPK2 (0.59) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL4376468 | 0.84 | MAPK14 (0.82) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL4378073 | 0.83 | MAPK14 (0.82) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL29593154 | 0.83 | MAPK14 (0.82) | MAPK14ROCK2MAPK12MAPK11STRADA | |
| SCHEMBL4488757 | 0.82 | MAPK14 (0.85) | MAPK14ROCK2MAPK12MAPK11STRADA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767309-B2 | Methods of synthesizing substituted pyridinone-pyridinyl compounds | ACLARIS THERAPEUTICS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230202999-A9 | METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767309-B2 | Methods of synthesizing substituted pyridinone-pyridinyl compounds | PIR, PUM1, ZRANB2 | MAPK14 2275/4885ROCK2 2348/4885MAPK12 1518/4885 |
| US-20230202999-A9 | METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | PIR, PUM1, ZRANB2 | MAPK14 2275/4885ROCK2 2348/4885MAPK12 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.